Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
Our analysis shows that O-chemo was more costly ( 40,477 for obinutuzumab vs 25,503 for rituximab) but more effective, with expected OS prolongation of 0.97 years (14.31 LYs for obinutuzumab vs 13.35 for rituximab). This corresponds to a 0.88 QALY gain (12.55 QALYs for obinutuzumab vs 11.68 QALYs for rituximab).
Obinutuzumab is different/superior to rituximab (chimeric) ofatumumab KidneyWk.
However, results of rituximab and obinutuzumab should be interpreted with caution, taking into consideration that obinutuzumab is administered at higher doses compared to rituximab. Although some earlier clinical studies of rituximab were disappointing 45, 46, subsequent trials demonstrated that higher doses of rituximab were associated with
by Y Chu Cited by 7vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL. PMBL
Four RCTs with 3465 patients compared obinutuzumab with rituximab in induction therapy of CD20 B-NHL. Meta-analyses showed that compared with rituximab, obinutuzumab significantly prolonged
by AS Freedman Cited by 1Outline Bendamustine plus rituximab R-CHOP Obinutuzumab-based regimens Lenalidomide plus rituximab or obinutuzumab.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody (mAb), recognizing a unique CD20 extracellular membrane epitope with enhanced antibody dependent cellular cytotoxicity (ADCC) vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL. PMBL cells
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are